• Nenhum resultado encontrado

Rev. Bras. Reumatol. vol.54 número3

N/A
N/A
Protected

Academic year: 2018

Share "Rev. Bras. Reumatol. vol.54 número3"

Copied!
3
0
0

Texto

(1)

R E V B R A S R E U M A T O L . 2 0 1 4 ;5 4 ( 3 ): 2 5 6

www.reumatologia.com.br

REVISTA BRASILEIRA DE

REUMATOLOGIA

Erratum

Erratum of volume 54, issue 1

Errata do volume 54, número 1

0482-5004/$ - see front matter. © 2014 Sociedade Brasileira de Reumatologia. Published by Elsevier Editora Ltda. All rights reserved. http://dx.doi.org/10.1016/j.rbre.2014.05.002

On the headings of the pages of the Brazilian Journal of Rheumatology, v. 54, n. 1, where it reads:

REV BRAS REUMATOL 2013;54(1): and the number of the pages comprehending the article,

it should read:

(2)
(3)

Referências

Documentos relacionados

The present study evaluated the balance in elderly individ- uals with and without knee OA during functional tasks such as standing up and sitting down from a chair and stair ascent

In the preoperative evaluation of patients with RA, in addi- tion to a routine history and physical examination applicable to all patients (a record of the surgical procedure that

Eficacy and safety of different doses and retreatment of rituximab: a randomised, placebo- controlled trialin patients who are biological naïve with active rheumatoid arthritis and

by renal biopsy in a series of 21 cases of dermatomyositis/ polymyositis, that the presence of nephritis was associated with membranous and proliferative mesangial

In young patients, although the major cause of low back pain has muscle origin, some clinical aspects must be consid- ered, as night pain, pain after trauma, hyperextension pain,

(B) Acute monoarthritis in right knee of a patient with mild Brazilian spotted fever, after a tick bite episode occurred in the Atlantic rainforest, São Sebastião, São Paulo

2 – Pearson correlation of circulating Treg cells (A) and CD3–CD19+ B cells (B) with lupus activity assessed by the systemic lupus erythematosus disease activity index

Eficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomized, double-blind,